Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Arcadia Biosciences (RKDA) over the last 12 years, with Q3 2025 value amounting to $3.1 million.

  • Arcadia Biosciences' Total Non-Current Liabilities rose 158.47% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year increase of 158.47%. This contributed to the annual value of $5.3 million for FY2024, which is 583.77% up from last year.
  • As of Q3 2025, Arcadia Biosciences' Total Non-Current Liabilities stood at $3.1 million, which was up 158.47% from $3.3 million recorded in Q2 2025.
  • Over the past 5 years, Arcadia Biosciences' Total Non-Current Liabilities peaked at $26.0 million during Q2 2021, and registered a low of $3.1 million during Q1 2025.
  • In the last 5 years, Arcadia Biosciences' Total Non-Current Liabilities had a median value of $6.1 million in 2023 and averaged $8.3 million.
  • In the last 5 years, Arcadia Biosciences' Total Non-Current Liabilities plummeted by 7598.06% in 2022 and then skyrocketed by 7977.91% in 2023.
  • Over the past 5 years, Arcadia Biosciences' Total Non-Current Liabilities (Quarter) stood at $10.7 million in 2021, then tumbled by 43.47% to $6.0 million in 2022, then decreased by 16.94% to $5.0 million in 2023, then grew by 5.84% to $5.3 million in 2024, then tumbled by 40.67% to $3.1 million in 2025.
  • Its last three reported values are $3.1 million in Q3 2025, $3.3 million for Q2 2025, and $3.1 million during Q1 2025.